Development of picornavirus-like particle vaccines

Vaccination has been the most effective and economical way of combating the spread of infectious disease. Virus-like particles (VLPs) against human and animal diseases caused by picornaviruses are actively being researched and developed as potential vaccines. Promising immunogenicity and protective efficacy data has been reported for VLPs produced using various expression systems. The translation of these VLPs into vaccine products requires further bioprocess development, underpinned by advanced analytical VLP characterization techniques. We overview approaches taken to effectively produce and purify these multiprotein VLPs to achieve the desired immune responses. The opportunities for developing VLP bioprocessing technologies for cost-effective and efficient vaccine manufacturing are highlighted.